Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease

Kiichiro Kanamitsu, Hisako Kakimoto, Akira Shimada, Yusei Nakata, Hiroaki Ochi, Hirokazu Watanabe, Yuka Iwasaki, Chiho Tokorodani, Akane Kanazawa, Hidehiko Maruyama, Mari Miyazawa, Ritsuo Nishiuchi, Kiyoshi Kikkawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background A recent study indicated the efficacy of the addition of prednisolone to i.v. immunoglobulin (IVIG) as initial treatment in patients with higher risk of IVIG resistance. Several different risk scores for predicting IVIG resistance have been proposed, mainly based on typical Kawasaki disease (KD) patients. We investigated the utility of the risk scores to predict IVIG resistance in incomplete KD. Methods Clinical records of incomplete KD patients who received a single dose of IVIG between 2005 and 2012 at Kochi Health Sciences Center were retrospectively reviewed. Patients were classified into an IVIG-responsive group and an IVIG-resistant group. The Kobayashi, Egami, and Sano risk scores were calculated for each patient and the proportion of high-risk patients was compared between the two groups for each risk score. Results For 51 incomplete KD patients, Kobayashi (66.7% vs 47.6%, P = 0.253), Egami (55.6% vs 38.1%, P = 0.274), and Sano (57.1% vs 10.8%, P = 0.068) risk scores identified a higher proportion of high-risk patients in the IVIG-resistant group compared with the IVIG-responsive group, but significant difference was not observed. Sano risk score had the highest OR (6.19; 95%CI: 1.00-38.26). Conclusions The proportion of patients identified as being at high risk for IVIG resistance using the Kobayashi, Egami, and Sano risk scores, respectively, was not significantly different between the IVIG-responsive group and the IVIG-resistant group for incomplete KD. Among the three risk scores, the Sano risk score has the best ability to predict IVIG resistance in incomplete KD.

Original languageEnglish
Pages (from-to)146-151
Number of pages6
JournalPediatrics International
Volume58
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Mucocutaneous Lymph Node Syndrome
Immunoglobulins
Prednisolone

Keywords

  • coronary artery lesion
  • i.v. immunoglobulin
  • incomplete Kawasaki disease
  • risk score

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease. / Kanamitsu, Kiichiro; Kakimoto, Hisako; Shimada, Akira; Nakata, Yusei; Ochi, Hiroaki; Watanabe, Hirokazu; Iwasaki, Yuka; Tokorodani, Chiho; Kanazawa, Akane; Maruyama, Hidehiko; Miyazawa, Mari; Nishiuchi, Ritsuo; Kikkawa, Kiyoshi.

In: Pediatrics International, Vol. 58, No. 2, 01.02.2016, p. 146-151.

Research output: Contribution to journalArticle

Kanamitsu, K, Kakimoto, H, Shimada, A, Nakata, Y, Ochi, H, Watanabe, H, Iwasaki, Y, Tokorodani, C, Kanazawa, A, Maruyama, H, Miyazawa, M, Nishiuchi, R & Kikkawa, K 2016, 'Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease', Pediatrics International, vol. 58, no. 2, pp. 146-151. https://doi.org/10.1111/ped.12755
Kanamitsu, Kiichiro ; Kakimoto, Hisako ; Shimada, Akira ; Nakata, Yusei ; Ochi, Hiroaki ; Watanabe, Hirokazu ; Iwasaki, Yuka ; Tokorodani, Chiho ; Kanazawa, Akane ; Maruyama, Hidehiko ; Miyazawa, Mari ; Nishiuchi, Ritsuo ; Kikkawa, Kiyoshi. / Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease. In: Pediatrics International. 2016 ; Vol. 58, No. 2. pp. 146-151.
@article{c655499a21544b748db9df90a9df5d88,
title = "Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease",
abstract = "Background A recent study indicated the efficacy of the addition of prednisolone to i.v. immunoglobulin (IVIG) as initial treatment in patients with higher risk of IVIG resistance. Several different risk scores for predicting IVIG resistance have been proposed, mainly based on typical Kawasaki disease (KD) patients. We investigated the utility of the risk scores to predict IVIG resistance in incomplete KD. Methods Clinical records of incomplete KD patients who received a single dose of IVIG between 2005 and 2012 at Kochi Health Sciences Center were retrospectively reviewed. Patients were classified into an IVIG-responsive group and an IVIG-resistant group. The Kobayashi, Egami, and Sano risk scores were calculated for each patient and the proportion of high-risk patients was compared between the two groups for each risk score. Results For 51 incomplete KD patients, Kobayashi (66.7{\%} vs 47.6{\%}, P = 0.253), Egami (55.6{\%} vs 38.1{\%}, P = 0.274), and Sano (57.1{\%} vs 10.8{\%}, P = 0.068) risk scores identified a higher proportion of high-risk patients in the IVIG-resistant group compared with the IVIG-responsive group, but significant difference was not observed. Sano risk score had the highest OR (6.19; 95{\%}CI: 1.00-38.26). Conclusions The proportion of patients identified as being at high risk for IVIG resistance using the Kobayashi, Egami, and Sano risk scores, respectively, was not significantly different between the IVIG-responsive group and the IVIG-resistant group for incomplete KD. Among the three risk scores, the Sano risk score has the best ability to predict IVIG resistance in incomplete KD.",
keywords = "coronary artery lesion, i.v. immunoglobulin, incomplete Kawasaki disease, risk score",
author = "Kiichiro Kanamitsu and Hisako Kakimoto and Akira Shimada and Yusei Nakata and Hiroaki Ochi and Hirokazu Watanabe and Yuka Iwasaki and Chiho Tokorodani and Akane Kanazawa and Hidehiko Maruyama and Mari Miyazawa and Ritsuo Nishiuchi and Kiyoshi Kikkawa",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/ped.12755",
language = "English",
volume = "58",
pages = "146--151",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease

AU - Kanamitsu, Kiichiro

AU - Kakimoto, Hisako

AU - Shimada, Akira

AU - Nakata, Yusei

AU - Ochi, Hiroaki

AU - Watanabe, Hirokazu

AU - Iwasaki, Yuka

AU - Tokorodani, Chiho

AU - Kanazawa, Akane

AU - Maruyama, Hidehiko

AU - Miyazawa, Mari

AU - Nishiuchi, Ritsuo

AU - Kikkawa, Kiyoshi

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background A recent study indicated the efficacy of the addition of prednisolone to i.v. immunoglobulin (IVIG) as initial treatment in patients with higher risk of IVIG resistance. Several different risk scores for predicting IVIG resistance have been proposed, mainly based on typical Kawasaki disease (KD) patients. We investigated the utility of the risk scores to predict IVIG resistance in incomplete KD. Methods Clinical records of incomplete KD patients who received a single dose of IVIG between 2005 and 2012 at Kochi Health Sciences Center were retrospectively reviewed. Patients were classified into an IVIG-responsive group and an IVIG-resistant group. The Kobayashi, Egami, and Sano risk scores were calculated for each patient and the proportion of high-risk patients was compared between the two groups for each risk score. Results For 51 incomplete KD patients, Kobayashi (66.7% vs 47.6%, P = 0.253), Egami (55.6% vs 38.1%, P = 0.274), and Sano (57.1% vs 10.8%, P = 0.068) risk scores identified a higher proportion of high-risk patients in the IVIG-resistant group compared with the IVIG-responsive group, but significant difference was not observed. Sano risk score had the highest OR (6.19; 95%CI: 1.00-38.26). Conclusions The proportion of patients identified as being at high risk for IVIG resistance using the Kobayashi, Egami, and Sano risk scores, respectively, was not significantly different between the IVIG-responsive group and the IVIG-resistant group for incomplete KD. Among the three risk scores, the Sano risk score has the best ability to predict IVIG resistance in incomplete KD.

AB - Background A recent study indicated the efficacy of the addition of prednisolone to i.v. immunoglobulin (IVIG) as initial treatment in patients with higher risk of IVIG resistance. Several different risk scores for predicting IVIG resistance have been proposed, mainly based on typical Kawasaki disease (KD) patients. We investigated the utility of the risk scores to predict IVIG resistance in incomplete KD. Methods Clinical records of incomplete KD patients who received a single dose of IVIG between 2005 and 2012 at Kochi Health Sciences Center were retrospectively reviewed. Patients were classified into an IVIG-responsive group and an IVIG-resistant group. The Kobayashi, Egami, and Sano risk scores were calculated for each patient and the proportion of high-risk patients was compared between the two groups for each risk score. Results For 51 incomplete KD patients, Kobayashi (66.7% vs 47.6%, P = 0.253), Egami (55.6% vs 38.1%, P = 0.274), and Sano (57.1% vs 10.8%, P = 0.068) risk scores identified a higher proportion of high-risk patients in the IVIG-resistant group compared with the IVIG-responsive group, but significant difference was not observed. Sano risk score had the highest OR (6.19; 95%CI: 1.00-38.26). Conclusions The proportion of patients identified as being at high risk for IVIG resistance using the Kobayashi, Egami, and Sano risk scores, respectively, was not significantly different between the IVIG-responsive group and the IVIG-resistant group for incomplete KD. Among the three risk scores, the Sano risk score has the best ability to predict IVIG resistance in incomplete KD.

KW - coronary artery lesion

KW - i.v. immunoglobulin

KW - incomplete Kawasaki disease

KW - risk score

UR - http://www.scopus.com/inward/record.url?scp=84959506761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959506761&partnerID=8YFLogxK

U2 - 10.1111/ped.12755

DO - 10.1111/ped.12755

M3 - Article

C2 - 26190225

AN - SCOPUS:84959506761

VL - 58

SP - 146

EP - 151

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 2

ER -